The dominance of Eylea is expected to persist in the foreseeable future

1 July 2020 (Last Updated July 1st, 2020 09:29)

Bayer/Regeneron’s Eylea (aflibercept) is a fusion protein utilised in the treatment of retinal diseases frequently exacerbated by choroidal neovascularisation, a process in which new blood vessels grow from over-expression of pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).

Roche/Genentech also has a portfolio of anti-VEGF products used to treat ophthalmic indications. Read more here.